search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


In vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques


- candidate number14963
- NTR NumberNTR4026
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR6-jun-2013
- Secondary IDsNL42902.031.12 MEC
- Public TitleIn vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques
- Scientific TitleIn vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques a pilot study
- ACRONYMRESPECT
- hypothesisThe aim of this pilot study is to investigate whether chemotherapy response can be detected with optical spectroscopy (diffuse reflectance and fluorescence spectroscopy) in patients with unresectable colorectal liver metastases receiving first line systemic therapy.
- Healt Condition(s) or Problem(s) studiedInoperable cancer, Colorectal metastised cancer
- Inclusion criteria1. Patients with unresectable colorectal liver metastases;
2. The liver lesions are safely accessible according to an intervention-radiologist;
3. First line systemic treatment with Capacitabin and Oxaliplatin or FOLFOX, both with or without biologicals;
4. Written informed consent >18y.
- Exclusion criteria1. Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy;
2. Patients with bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgery;
3. Patients using any anti-coagulant medication at the time of biopsy: all aspirin derivatives, coumarines, platelet function inhibitors, heparins (including LMWHs) and oral factor Xa inhibitors are not allowed, unless medication can either be safely stopped or counteracted;
4. Patients with indequate hematology and coagulation status as measured by:
* Hb < 6.0 mmol/L;
* Platelet count < 100 x 109/L;
* PT < 1.5 x Upper limit of normal (ULN);
* APTT < 1.5 x ULN;
* PT-INR < 1.5 on the day of biopsy in patients using coumarines;
* Patients known with contraindications for lidocaine (or its derivatives).
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 21-jun-2013
- planned closingdate31-dec-2013
- Target number of participants22
- InterventionsHistological biopsy procedure (standard core biopsy procedure) - before and after stardard of care chemotherapy.
- Primary outcomeThe aim of this pilot study is to investigate whether chemotherapy response can be detected with optical spectroscopy (diffuse reflectance and fluorescence spectroscopy) in patients with unresectable colorectal liver metastases receiving first line systemic therapy.
- Secondary outcome1. To compare the accuracy of chemotherapy response using optical spectroscopy with standardized RECIST criteria;
2. To correlate spectroscopic measurements with tissue characteristics from biopsies;
3. During the measurement procedure, possible improvements to the measurement hardware will be recorded which can provide information for possible alterations of hardware design for improved clinical applicability in the future.
- TimepointsDay 0 and day of first response monitoring
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. Torre Bydlon
- CONTACT for SCIENTIFIC QUERIESDr. Torre Bydlon
- Sponsor/Initiator Philips Research Eindhoven
- Funding
(Source(s) of Monetary or Material Support)
Philips
- PublicationsN/A
- Brief summaryResponse monitoring of patients undergoing systemic therapy for colorectal liver metastases in the era of new targeted drugs is troublesome and the development of new monitoring tools is needed. The primary aim of this pilot study is to investigate whether chemotherapy response can be detected with optical spectroscopy in patients with unresectable colorectal liver metastases receiving first line systemic therapy. Optical spectroscopy measurements will be acquired from normal liver tissue and the liver metastasis; a biopsy will also be taken. This will be done prior to the start of systemic therapy and at the first response monitoring moment.
- Main changes (audit trail)1-7-2013:
Modification:
The Percuspect study is extended to breast cancer patients. 36 additional patients with this condition will be included. METC of NKI approved this modification per April 25, 2013. Due to this change, the inclusion criteria are extended with the following:

Breast Specific Inclusion criteria
- Breast patients with a BIRADS score 4 or 5

Breast Specific Exclusion criteria
- Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy
- Patients who have breast implants
- Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions).
- RECORD6-jun-2013 - 1-jul-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl